LONDON (Reuters) - A once-daily injection of Sanofi-Aventis's insulin drug Lantus controls blood sugar as effectively as Eli Lilly's Humalog, which needs to be taken three times daily, researchers ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

Eli Lilly has announced that it is reducing the list price of its insulin by 70% and capping out-of-pocket costs at $35 a month as part of its Insulin Value Program. Effective immediately, Lilly will ...

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...

French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product Lantus ...

March 16 (UPI) --A third drug company is cutting the price of insulin to $35, following competitors Eli Lilly and Novo Nordisk in heeding pressure from the Biden administration. Sanofi's Lantus ...

[THE INVESTOR] Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on April 13, intent on challenging the original ...

The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...